MADAM-6

Last updated
MADAM-6
Madam-6.png
Names
Preferred IUPAC name
N-Methyl-1-(6-methyl-2H-1,3-benzodioxol-5-yl)propan-2-amine
Other names
6-Methyl-MDMA
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C12H17NO2/c1-8-4-11-12(15-7-14-11)6-10(8)5-9(2)13-3/h4,6,9,13H,5,7H2,1-3H3
    Key: CRQPDNIUPWXPNK-UHFFFAOYSA-N
  • C1(=CC2=C(C=C1CC(C)NC)OCO2)C
Properties
C12H17NO2
Molar mass 207.273 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

MADAM-6, or 2, N-dimethyl-4,5-methylenedioxyamphetamine, is a lesser-known recreational drug of the methamphetamine class, similar in structure to MDMA (ecstasy). [1] MADAM-6 was first synthesized by Alexander Shulgin. [2] In Shulgin's book PiHKAL , the minimum dosage is listed as greater than 280 mg, and the duration is unknown. [2] MADAM-6 produces few to no effects and Shulgin describes it as "not active". [2] Very little data exists about the pharmacological properties, metabolism, and toxicity of MADAM-6.

MADAM-6 has been studied for its potential antiparkinsonian effects. [3] However, no clinical trials suggest the drug is effective against Parkinson's disease.

See also

Related Research Articles

<i>PiHKAL</i> 1991 book by Alexander Shulgin and Ann Shulgin

PiHKAL: A Chemical Love Story is a book by Dr. Alexander Shulgin and Ann Shulgin, published in 1991. The subject of the work is psychoactive phenethylamine chemical derivatives, notably those that act as psychedelics and/or empathogen-entactogens. The main title, PiHKAL, is an acronym that stands for "Phenethylamines I Have Known and Loved."

<span class="mw-page-title-main">3,4-Methylenedioxyamphetamine</span> Empathogen-entactogen, psychostimulant, and psychedelic drug of the amphetamine family

3,4-Methylenedioxyamphetamine is an empathogen-entactogen, psychostimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). In most countries, the drug is a controlled substance and its possession and sale are illegal.

<span class="mw-page-title-main">Lophophine</span> Chemical compound

Lophophine is a putative psychedelic and entactogen drug of the methylenedioxyphenethylamine class. It is the α-demethylated homologue of MMDA, and is also closely related to mescaline.

<span class="mw-page-title-main">MMDA (drug)</span> Entactogen drug

MMDA is a psychedelic and entactogen drug of the amphetamine class. It is an analogue of lophophine, MDA, and MDMA.

<span class="mw-page-title-main">DMMDA-2</span> Chemical compound

DMMDA-2 is a psychedelic phenethylamine discussed by Alexander Shulgin in his book PiHKAL ; however, he was not the first to synthesize it. Shulgin comments in his book that a 50 milligram dose of DMMDA-2 produces similar effects to MDA. DMMDA-2 can be synthesized from dillapiole.

3,4-Methylenedioxy-<i>N</i>-hydroxyamphetamine Psychedelic amphetamine

3,4-Methylenedioxy-N-hydroxyamphetamine is an entactogen, psychedelic, and stimulant of the phenethylamine and amphetamine chemical classes. It is the N-hydroxy homologue of MDA, and the N-desmethyl homologue of MDHMA. MDOH was first synthesized and assayed by Alexander Shulgin. In his book PiHKAL, Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 3–6 hours. He describes MDOH as being very psychedelic and producing increased pleasure in beauty and nature. He also mentioned several negative side effects also seen with MDMA ("Ecstasy") such as difficulty urinating and internal dryness.

<span class="mw-page-title-main">Substituted methylenedioxyphenethylamine</span> Class of psychoactive drugs

The substituted methylenedioxyphenethylamines represent a diverse chemical class of compounds derived from phenethylamines. This category encompasses numerous psychoactive substances with entactogenic, psychedelic, and/or stimulant properties, in addition to entheogens. These compounds find application as research chemicals, designer drugs, and recreational substances.

<span class="mw-page-title-main">EDMA</span> Chemical compound

3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the methamphetamine class. It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring. EDMA was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours. According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects. Scientific research has demonstrated that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release.

3,4-Methylenedioxy-<i>N</i>-hydroxy-<i>N</i>-methylamphetamine Chemical compound

3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine is an entactogen, psychedelic, and stimulant of the phenethylamine and amphetamine chemical classes. It is the N-hydroxy homologue of MDMA ("Ecstasy"), and the N-methyl homologue of MDOH. MDHMA was first synthesized and assayed by Alexander Shulgin. In his book PiHKAL, Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 4–8 hours. He describes MDHMA as causing entactogenic and open MDMA-like effects, easing communication, and increasing appreciation of the senses.

<span class="mw-page-title-main">2-Bromo-4,5-methylenedioxyamphetamine</span> Substituted amphetamine psychedelic drug

2-Bromo-4,5-methylenedioxyamphetamine (6-Bromo-MDA) is a lesser-known psychedelic drug and a substituted amphetamine. It was first synthesized by Alexander Shulgin. In his book PiHKAL, the dose is listed as 350 mg and the duration unknown. It produces stimulant effects but with no psychedelic or empathogenic action. Very little data exists about its pharmacological properties, metabolism, and toxicity.

<span class="mw-page-title-main">DMMDA</span> Psychedelic drug

2,5-Dimethoxy-3,4-methylenedioxyamphetamine is a lesser-known psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized by Alexander Shulgin and was described in his book PiHKAL. Shulgin listed the dosage as 30–75 mg and the duration as 6–8 hours. He reported DMMDA as producing LSD-like images, mydriasis, ataxia, and time dilation. DMMDA isn't mentioned much in literature outside PiHKAL unlike 2C-B.

<span class="mw-page-title-main">1,3-Benzodioxolylbutanamine</span> Enactogenic drug of the phenethylamine class

1,3-Benzodioxolylbutanamine is an entactogenic drug of the phenethylamine chemical class. It is the α-ethyl analog of MDPEA and MDA and the methylenedioxy analogue of α-ethylphenethylamine.

3,4-Methylenedioxy-<i>N</i>-isopropylamphetamine Chemical compound

3,4-Methylenedioxy-N-isopropylamphetamine is a psychoactive drug of the phenethylamine and amphetamine chemical classes which acts as an entactogen, psychedelic, and stimulant. It is the N-isopropyl analogue of 3,4-methylenedioxyamphetamine (MDA). MDIP was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 250 mg. MDIP produces a mild threshold. Very little is known about the pharmacology, pharmacokinetics, effects, and toxicity of MDIP.

<span class="mw-page-title-main">F-2 (drug)</span> Psychedelic drug

F-2, or 6-(2-aminopropyl)-5-methoxy-2-methyl-2,3-dihydrobenzofuran, is a lesser-known psychedelic drug. F-2 was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 15 mg, and the duration unknown. F-2 produces few to no effects at this dose in humans. Animal studies showed it to substitute for the psychedelic drug DOM, but with less than one tenth the potency.

<i>para</i>-Methoxy-<i>N</i>-methylamphetamine Stimulant and psychedelic designer drug

para-Methoxy-N-methylamphetamine, chemically known as methyl-MA, 4-methoxy-N-methylamphetamine, and 4-MMA is a stimulant and psychedelic drug closely related to the amphetamine-class serotonergic drug para-methoxyamphetamine (PMA). PMMA is the 4-methoxy analog of methamphetamine. Little is known about the pharmacological properties, metabolism, and toxicity of PMMA; because of its structural similarity to PMA, which has known toxicity in humans, it is thought to have considerable potential to cause harmful side effects or death in overdose. In the early 2010s, a number of deaths in users of the drug MDMA were linked to misrepresented tablets and capsules of PMMA.

<span class="mw-page-title-main">MMDA-2</span> Psychedelic drug

MMDA-2 (2-methoxy-4,5-methylenedioxyamphetamine) is a psychedelic drug of the amphetamine class. It is closely related to MMDA and MDA.

<span class="mw-page-title-main">Methyl-MMDA-2</span> Chemical compound

N-Methyl-2-methoxy-4,5-methylenedioxyamphetamine is a psychedelic drug of the amphetamine class. It is the N-methylated derivative of MMDA-2, and it is also an analog of MDMA and 6-methyl-MDA.

<span class="mw-page-title-main">Methylenedioxyallylamphetamine</span> Chemical compound

Methylenedioxyallylamphetamine is a lesser-known psychedelic drug. It is also the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 180 mg, and the duration unknown. MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.

<span class="mw-page-title-main">Methylenedioxybutylamphetamine</span> Chemical compound

Methylenedioxybutylamphetamine is a lesser-known psychedelic drug. It is also the N-butyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDBU was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 40 mg, and the duration unknown. MDBU produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDBU.

<span class="mw-page-title-main">Methylenedioxydimethylamphetamine</span> Chemical compound

3,4-Methylenedioxy-N,N-dimethylamphetamine (MDDM) is a lesser-known research chemical. It is also the N,N-dimethyl analog of 3,4-methylenedioxyamphetamine (MDA). MDDM was first synthesized by Alexander Shulgin. In his book PiHKAL , the dosage is unspecified and the duration unknown. MDDM produces only mild effects that are not well characterized in PiHKAL. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDDM. This compound is however occasionally encountered as an impurity in 3,4-methylenedioxy-N-methylamphetamine (MDMA) which has been synthesized by methylation of MDA using methylating reagents such as methyl iodide. An excess of reagent or a reaction temperature that is too high results in some double methylation of the amine nitrogen, yielding MDDM as well as MDMA. The presence of MDDM as an impurity can thus reveal which synthetic route was used to manufacture seized samples of MDMA.

References

  1. Patt, M; Gündisch, D; Wüllner, U; Blocher, A; Kovar, K. -A; Machulla, H. -J (1999). "N-[11C]methyl-3,4-methylenedioxyamphetamine (Ecstasy) and 2-methyl-N-[11C]methyl-4,5-methylenedioxyamphetamine: Synthesis and biodistribution studies". Journal of Radioanalytical and Nuclear Chemistry. 240 (2): 535. doi:10.1007/BF02349410. S2CID   96272983.
  2. 1 2 3 MADAM-6 entry in PiHKAL
  3. USpatent US2015025063,Caron; Gainetdinov& Sotnikova,"Antiparkinsonian Action Of Phenylisopropylamines",published 2014-09-30,issued 2015-01-22